Description

Zolmigren (zolmitriptan) Coated Tablets 2.5 mg. №2

Ingredients

Active ingredient: Zolmitriptan 2.5 mg. Other ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, triacetin.

Dosage

Dosage: The usual dose is 2.5 mg taken as soon as migraine symptoms appear. A second dose may be taken after 2 hours if needed. Maximum dose: 10 mg in 24 hours.

Indications

Indications: Zolmigren is indicated for the acute treatment of migraine attacks with or without aura in adults.

Contraindications

Contraindications: Do not use Zolmigren if you have uncontrolled hypertension, ischemic heart disease, history of stroke or transient ischemic attack, peripheral vascular disease, or severe hepatic impairment.

Directions

Directions: Swallow the tablet whole with water. Do not crush, chew, or break the tablet. It can be taken with or without food.

Scientific Evidence

Zolmitriptan, the active ingredient in Zolmigren, is a selective serotonin receptor agonist that acts on the 5-HT1B/1D receptors in the brain. These receptors are involved in the pathophysiology of migraine. Clinical trials have shown that zolmitriptan is effective in relieving migraine symptoms, including pain, nausea, and sensitivity to light and sound.

Additional Information

Zolmigren coated tablets have been shown to provide rapid relief from migraine attacks, with many patients experiencing significant improvement within 2 hours of taking the medication. It is important to follow the recommended dosage and not exceed the maximum daily dose to avoid potential side effects.

Zolmigren (zolmitriptan) has been extensively studied in clinical trials, demonstrating its efficacy and safety in the treatment of migraines. Research published in the Journal of Headache and Pain highlighted the significant reduction in pain intensity and associated symptoms in patients treated with zolmitriptan compared to a placebo group.

The pharmacological action of zolmitriptan involves vasoconstriction of the dilated cranial blood vessels and inhibition of pro-inflammatory neuropeptide release, contributing to the relief of migraine symptoms. Compared to other triptans, zolmitriptan has shown similar efficacy but may have a faster onset of action in some individuals, making it a valuable option for acute migraine management.